Dutch pediatricians often diagnosed Henoch-Schönlein purpura on purpura alone
A nationwide survey of Dutch pediatricians found that Henoch-Schönlein purpura in children was diagnosed more broadly than later classification standards would support, raising concern that some cases were being labeled too early or too loosely. In 2004, physicians across the Netherlands reported 232 children and adolescents with the condition, producing an incidence estimate of 6.1 per 100,000 children aged 0 to 18 years. The case mix was not trivial: 29% presented with renal symptoms, a feature that immediately changes the intensity and duration of follow-up in everyday pediatric practice.
The study did more than count cases. It also exposed how pediatricians were deciding who qualified for the diagnosis, and that process leaned heavily on a single clinical sign. Eighty percent considered isolated purpura, without hematological abnormalities, sufficient for the diagnosis of HSP in children. In real-world terms, that means a rash alone often opened the door to a vasculitis label, even before the broader syndrome had fully declared itself.
Classification drift between bedside diagnosis and formal criteria
Henoch-Schönlein purpura, also called IgA vasculitis, remains a clinical diagnosis at the bedside, but the threshold for making it should not be so low that other causes of purpura are swept aside. The concern in this Dutch cohort is not academic. Purpura without thrombocytopenia can reflect a broad differential, and a diagnosis made on appearance alone can create a chain of follow-up, parental anxiety, and repeated testing that may not be necessary if the presentation is incomplete.
The investigators compared pediatric practice against the 2006 EULAR/PReS endorsed consensus criteria for childhood vasculitides. By those standards, only 160 of the 179 patients included in the analysis would have met criteria for HSP. The gap between everyday diagnosis and formal classification is the central finding of the study. It suggests that a substantial minority of children were being managed as if they had HSP despite not satisfying later consensus criteria.
Skin biopsy did not always confirm IgA vasculitis
Histology added another layer of uncertainty. Among the 17 skin biopsies performed, only 9 showed IgA deposits, a finding present in just 53% of sampled cases. That result does not invalidate the diagnosis in every child, because biopsy yield depends on timing, sampling, and lesion selection. Even so, the modest positivity rate reinforces how imperfect the clinical label can be when pathology is used as a check on diagnosis rather than a routine confirmation step.
A biopsy that fails to demonstrate IgA does not automatically rule out the disease, but it does remind clinicians that a purpuric eruption is not a diagnosis by itself. In children with limited skin findings and no renal involvement, the threshold for certainty should be higher, not lower. The study’s biopsy data fit that message cleanly.
Renal symptoms drove longer surveillance, but follow-up often extended anyway
Renal involvement changed management in predictable ways. The follow-up period was longer when renal symptoms were present at presentation, which reflects standard pediatric caution because kidney disease in HSP can evolve after the rash and abdominal symptoms begin. Yet the study also found that 45% of patients without renal symptoms would still be followed for more than one year. In practice, that means nearly half of the children without initial kidney involvement were still tied to prolonged monitoring, despite lacking the feature most likely to justify extended surveillance.
A one-size-fits-all follow-up plan can be costly in time and attention. Children without renal findings may continue to receive repeated visits and urinalysis because the initial diagnostic label encourages caution, even when their subsequent risk appears low. The study does not measure the downstream burden directly, but the pattern is easy to see: an expansive diagnostic habit can stretch follow-up well beyond the subgroup that clearly needs it.
Why isolated purpura can be a misleading anchor
Purpura is the most visible sign of HSP, which makes it an easy anchor for diagnosis. It is also the least specific when seen alone. Once a child has a non-thrombocytopenic purpuric rash, clinicians may feel they are already inside the diagnostic frame of HSP, even if abdominal pain, arthralgia, or renal findings have not emerged. That shortcut is understandable, especially in busy pediatric practice, but it risks conflating a sign with a syndrome.
The pathophysiology of HSP is immune-mediated small-vessel vasculitis, and vascular inflammation can involve skin, gut, joints, and kidneys in varying combinations. Because the full clinical picture may evolve over time, early recognition matters. Yet early recognition should not become premature closure. The study shows the tension between needing to identify evolving vasculitis and avoiding a diagnosis based solely on one manifestation of it.
One-symptom diagnosis can be clinically expensive.
What the Dutch data say about overdiagnosis
The study’s conclusion is blunt: using isolated non-thrombocytopenic purpura as the only criterion to diagnose HSP in children may lead to overdiagnosis and unnecessary follow-up. The numbers support that concern. Between the 232 reported cases, the 179 patients analyzed against later consensus criteria, and the 160 who would have met EULAR/PReS standards, there is enough separation to show that diagnostic thresholds were looser in routine practice than in formal classification.
This does not mean pediatricians were careless. It means the condition sits in a gray zone where an early rash can be persuasive, yet not decisive. When renal symptoms are absent, and when biopsy confirmation is unavailable or negative, a diagnosis made too readily can lock a child into months of surveillance without clear benefit. In a disorder that often resolves, precision in the first diagnostic step matters because it determines how long the child remains a patient in the system.
The study leaves a practical challenge for pediatric care in the Netherlands and beyond: when purpura appears in a child, how much additional evidence is enough to name HSP, and how much follow-up is justified once the diagnosis has been made? The data support a narrower approach than many clinicians were using in 2004, especially for children who present with skin findings alone and no renal involvement.